Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure

World Journal of Urology

Volumn 33, Issue 7, 2015, Pages 937-944

  Azzouzi, Abdel Rahmene ^a   Lebdai, Souhil ^a   Benzaghou, Fawzi ^b   Stief, Christian ^c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b STEBA Biotech   (France)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Focal therapy; Localized prostate cancer; Vascular targeted photodynamic therapy; WST11 TOOKAD Soluble

Indexed keywords

BACTERIOCHLOROPHYLL; PALLADIUM-BACTERIOPHEOPHORBIDE; PHOTOSENSITIZING AGENT;

HUMAN; MALE; PHOTOCHEMOTHERAPY; PROCEDURES; PROSTATIC NEOPLASMS; STANDARDS;

BACTERIOCHLOROPHYLLS; HUMANS; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSTATIC NEOPLASMS;

EID: 84933179739     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-015-1535-2     Document Type: Article

References (11)

1. ® Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int 112:766–774
2. Moore CM, Azzouzi AR, Barret E, Villers A, Muir G, Barber N, Trachtenberg J, Arumainayagam N, Gaillac B, Allen C, Schertz A, Emberton M (2014) Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localized prostate cancer using WST11-vascular targeted photodynamic (VTP) therapy. BJU Int. doi:10.1111/bju.12816
3. Moore CM, Pendse D, Emberton M (2009) Photodynamic therapy for prostate cancer—a review of current status and future promise. Nat Clin Pract Urol 6:18–30
4. Brown SB, Brown EA, Walker I (2004) The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 5:497–508
5. Brandis A, Mazor O, Neumark E, Rosenbach-Belkin V, Salomon Y, Scherz A (2005) Novel water-soluble bacteriochlorophyll derivatives for vascular-targeted photodynamic therapy: synthesis, solubility, phototoxicity and the effect of serum proteins. Photochem Photobiol 81:983–993
6. Vakrat-Haglili Y, Weiner L, Brumfeld V, Brandis A, Salomon Y, McLlroy B, Wilson BC, Pawlak A, Rozanowska M, Sarna T, Scherz A (2005) The microenvironment effect on the generation of reactive oxygen species by pd-bacteriopheophorbide. J Am Chem Soc 127:6487–6497
7. Borle F, Radu A, Fontolliet C, van den Bergh H, Monnier P, Wagnieres G (2003) Selectivity of the photosensitiser TOOKAD for photodynamic therapy evaluated in the syrian golden hamster cheek pouch tumour model. Br J Cancer 89:2320–2326
8. Koudinova NV, Pinthus JH, Brandis A, Brenner O, Bendel P, Ramon J, Eshhar Z, Scherz A, Salomon Y (2003) Photodynamic therapy with Pd-bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int J Cancer 104:782–789
9. Kelleher DK, Thews O, Scherz A, Salomon Y, Vaupel P (2004) Perfusion, oxygenation status and growth of experimental tumors upon photodynamic therapy with Pd-bacteriopheophorbide. Int J Oncol 24:1505–1511
10. Eymerit-Morin C, Zidane M, Lebdai S, Triau S, Azzouzi AR, Rousselet MC (2013) Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer. Virchows Arch 463(4):547–552
11. ® Soluble WST11. Phys Med Biol 56:4771–4783